


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application. The following amendments do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed. Applicants reserve the right to pursue the subject matter of the cancelled claims in this or any other appropriate patent application.

Complete Listing of Claims:

1-21. (Canceled)

22. (Withdrawn) A method of treating an HIV infected patient comprising administering to the patient a pharmaceutical composition comprising a compound in a dose effective to reduce viral propagation wherein the compound has a structure according to Formula (A) or Formula (B)




wherein R₁ is optionally substituted lower alkyl, halogen, or CF₃,

R₂ is ~~a substituted naphthyl~~ ~~optionally substituted cycloalkyl~~, ~~optionally substituted aryl~~, ~~optionally substituted quinoline~~, or ~~optionally substituted isoquinoline~~; and

R₃, R₄, and R₅ are independently hydrogen, halogen, optionally substituted alkyl, S-alkyl, CF₃, heterocycle, NR'R'', S(O)₂R', or C(O)R', and wherein R' and R'' are independently NH₂, NHAalkyl, NHAcyl, NAlkylAcyl, N(Alkyl)₂, O-alkyl, acyl, aryl, alkyl, heterocycle, or R' and R'' form a ring.

23-42. (Canceled)

43. (Currently Amended) A compound having a structure according to Formula (VI)



wherein HET is a disubstituted 1,2,4-triazole ~~or a disubstituted imidazole~~, wherein at least one substituent of the 1,2,4-triazole ~~or imidazole~~ is a monosubstituted aryl naphthyl that is covalently bound to a nitrogen of the 1,2,4-triazole and the other substituent is an

~~optionally substituted lower alkyl or a halogen or imidazole; selected from the group consisting of a monosubstituted naphthyl, a disubstituted naphthyl, a trisubstituted naphthyl, a monosubstituted quinoline, a disubstituted quinoline, a trisubstituted quinoline, a monosubstituted isoquinoline, a disubstituted isoquinoline, and a trisubstituted isoquinoline;~~

W is O, S, S(O), S(O)₂, NH, NR₁ or CH₂;

R₁ and R₂ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, halogen, OH, SH, NH₂, N₃, O-alkyl, or CH₂OH;

Y is O, S, or NR₃, wherein R₃ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, hydroxy, O-alkyl, or CH₂OH;

R₄ is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and


R₅ is an ortho-substituted phenyl, which is optionally further substituted,

or a pharmacologically acceptable salt thereof.

44. (Currently Amended) The compound of claim 43 wherein R₁, R₂, and R₄ are hydrogen, ~~and wherein one substituent of the 1,2,4 triazole or imidazole is an optionally substituted lower alkyl or halogen and the other substituent is a substituted aryl naphthyl that is covalently bound to a nitrogen of the 1,2,4 triazole or imidazole; selected from the group consisting of a monosubstituted naphthyl, a disubstituted naphthyl, a trisubstituted naphthyl, a monosubstituted quinoline, a disubstituted quinoline, a trisubstituted quinoline, a monosubstituted isoquinoline, a disubstituted isoquinoline, and a trisubstituted isoquinoline.~~

45. (Original) The compound of claim 44 wherein Y is O.

46. (Previously Presented) A compound having a structure according to Formula (A)



wherein R₁ is optionally substituted lower alkyl, or halogen,


R₂ is a substituted naphthyl; and

R₃, R₄, and R₅ are independently hydrogen, halogen, optionally substituted alkyl, S-alkyl, CF₃, heterocycle, NR'R'', S(O)₂R', or C(O)R', and wherein R' and R'' are independently NH₂, NHAalkyl, NHAcyl, NAlkylAcyl, N(Alkyl)₂, O-alkyl, acyl, aryl, alkyl, heterocycle, or R' and R'' form a ring,

or a pharmacologically acceptable salt thereof.

47-51. (Canceled).

52. (Previously Presented) A compound having the following chemical structure



53. (Previously Presented) The compound of claim 46, wherein R₂ is a mono-substituted naphthyl.